Abstract
Oxaliplatin is one of the most widely used anticancer drugs representing the cornerstone of the treatment of colorectal cancer. Yet a number of side effects, including oxaliplatin- induced peripheral neurotoxicity (OIPN) which represents a dose-limiting side effect in the clinical use of oxaliplatin, limit its use and a better understanding of its pathogenesis would offer a great opportunity to improve the “quality of survival” of cancer patients. So far, no treatment able to prevent or limit OIPN has been approved, and one of the reasons for this unmet clinical need is the incomplete knowledge of its pathogenesis preventing the development of rationalebased pharmacological interventions.
Preclinical and clinical evidence raised the hypothesis that intracellular calcium-related events might play an important role in the onset of OIPN. Yet, the results of mechanistic pre-clinical studies appear inconsistent and, therefore, their relevance in neuroprotective drugs design is still uncertain. Indeed, it is at present unclear whether aberrant calcium signalling is the key pathogenetic moment or whether it just constitutes the mediator of the clinical phenotype.
This review will summarize the preclinical results involving calcium-related events and OIPN with the aim to provide an updated overview of the available evidence and highlight the most promising strategies to design effective neuroprotective drugs. In particular, we will focus on the pre-clinical evidence suggesting that TRPV1, TRPM8 or TRPA1 might be involved, as these appear particularly amenable to pharmacological modulation.
Keywords: Oxaliplatin, calcium, neurotoxicity, pathogenesis, therapy, preclinical, in vitro.
Current Medicinal Chemistry
Title:Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy
Volume: 22 Issue: 32
Author(s): Paola Marmiroli, Guido Cavaletti, Valentina Carozzi, Beatrice Riva, Dmitry Lim and Armando A. Genazzani
Affiliation:
Keywords: Oxaliplatin, calcium, neurotoxicity, pathogenesis, therapy, preclinical, in vitro.
Abstract: Oxaliplatin is one of the most widely used anticancer drugs representing the cornerstone of the treatment of colorectal cancer. Yet a number of side effects, including oxaliplatin- induced peripheral neurotoxicity (OIPN) which represents a dose-limiting side effect in the clinical use of oxaliplatin, limit its use and a better understanding of its pathogenesis would offer a great opportunity to improve the “quality of survival” of cancer patients. So far, no treatment able to prevent or limit OIPN has been approved, and one of the reasons for this unmet clinical need is the incomplete knowledge of its pathogenesis preventing the development of rationalebased pharmacological interventions.
Preclinical and clinical evidence raised the hypothesis that intracellular calcium-related events might play an important role in the onset of OIPN. Yet, the results of mechanistic pre-clinical studies appear inconsistent and, therefore, their relevance in neuroprotective drugs design is still uncertain. Indeed, it is at present unclear whether aberrant calcium signalling is the key pathogenetic moment or whether it just constitutes the mediator of the clinical phenotype.
This review will summarize the preclinical results involving calcium-related events and OIPN with the aim to provide an updated overview of the available evidence and highlight the most promising strategies to design effective neuroprotective drugs. In particular, we will focus on the pre-clinical evidence suggesting that TRPV1, TRPM8 or TRPA1 might be involved, as these appear particularly amenable to pharmacological modulation.
Export Options
About this article
Cite this article as:
Marmiroli Paola, Cavaletti Guido, Carozzi Valentina, Riva Beatrice, Lim Dmitry and Genazzani A. Armando, Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy, Current Medicinal Chemistry 2015; 22 (32) . https://dx.doi.org/10.2174/0929867322666151001121302
DOI https://dx.doi.org/10.2174/0929867322666151001121302 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Onco-Surgical Management of Colo-Rectal Liver Metastases in Older Patients: A New Frontier in the 3<sup>rd</sup> Millennium
Anti-Cancer Agents in Medicinal Chemistry Exploring the Management of Statin Intolerant Patients: 2016 and Beyond
Current Vascular Pharmacology Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry FoxQ1 is a Novel Molecular Target for Pancreatic Cancer and is Associated with Poor Prognosis
Current Molecular Medicine Subject index to volume 3
Current Cancer Drug Targets Mechanisms Underlying Chemopreventive Effects of Flavonoids via Multiple Signaling Nodes within Nrf2-ARE and AhR-XRE Gene Regulatory Networks
Current Chemical Biology MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype
MicroRNA Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals
Current Medical Imaging CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases
Current Gene Therapy New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry Magnetic Nanoparticles: A Review on Stratagems of Fabrication an d its Biomedical Applications
Recent Patents on Drug Delivery & Formulation Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery Colon as Target for Drug Delivery
Current Drug Therapy Targeting Epigenetic Modifiers in Cancer
Current Medicinal Chemistry Treatment Directed to Signalling Molecules in Patients with Advanced Differentiated Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design Developments in Synthesis of the Anti-inflammatory Drug, Celecoxib: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Can Dietary Polyphenols Prevent the Formation of Toxic Compounds from Maillard Reaction?
Current Drug Metabolism Metabolites of Dietary Protein and Peptides by Intestinal Microbes and their Impacts on Gut
Current Protein & Peptide Science